BRAF and melanoma: The rapid transition from scientific findings to clinical application is exemplified by both the finding of BRAF mutations in melanoma in 2002 and FDA approval of vemurafenib for this indication in 2011 and that of the initial finding of EML4-ALK in 2007 and FDA approval of crizotinib in 2011.